Key facts
- First Ascent Biomedical’s last known valuation is $10.6M (Oct 2022).
- It has raised $7.2M; the latest was Grant ($1.7M) in Mar 2025.
- Notable investors include Techstars, Impact Assets, IAG Capital Partners, CancerX (USA), Pennsylvania Department of Community and Economic Development — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for First Ascent Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for First Ascent Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About First Ascent Biomedical
Developer of a drug prediction platform designed to deliver both treatment planning for cancer patients and drug development tools for pharma. The company's platform utilizes AI and therapy-resistant cell technologies to offer treatment plans that provide affordable cancer treatment options while reducing failed treatment regimens, enabling patients to have deep insight into biomarker discovery and trial population development.
- Sector
- Healthcare
- HQ
- Miami, FL, United States
- Founded
- 2018
- Employees
- 8
- Website
- firstascentbiomedical.com/
- Ownership
- Privately Held (backing)
First Ascent Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in First Ascent Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on First Ascent Biomedical in its N-PORT filings yet. We sweep new filings monthly.